806 related articles for article (PubMed ID: 24492433)
21. Mechanisms of action of BCG in superficial bladder cancer.
Ratliff TL
Prog Clin Biol Res; 1992; 378():103-9. PubMed ID: 1301570
[No Abstract] [Full Text] [Related]
22. Modulation of fibronectin-mediated Bacillus Calmette-Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways.
Hudson MA; Brown EJ; Ritchey JK; Ratliff TL
Cancer Res; 1991 Jul; 51(14):3726-32. PubMed ID: 2065329
[TBL] [Abstract][Full Text] [Related]
23. The immunotherapeutic effects of recombinant Bacillus Calmette-Guérin resistant to antimicrobial peptides on bladder cancer cells.
Cho MJ; Kim MJ; Kim K; Choi YW; Lee SJ; Whang YM; Chang IH
Biochem Biophys Res Commun; 2019 Jan; 509(1):167-174. PubMed ID: 30579607
[TBL] [Abstract][Full Text] [Related]
24. Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review.
Patard JJ; Saint F; Velotti F; Abbou CC; Chopin DK
Urol Res; 1998; 26(3):155-9. PubMed ID: 9694595
[TBL] [Abstract][Full Text] [Related]
25. Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer.
Begnini KR; Buss JH; Collares T; Seixas FK
Appl Microbiol Biotechnol; 2015 May; 99(9):3741-54. PubMed ID: 25794874
[TBL] [Abstract][Full Text] [Related]
26. Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall.
Böhle A; Gerdes J; Ulmer AJ; Hofstetter AG; Flad HD
J Urol; 1990 Jul; 144(1):53-8. PubMed ID: 2359181
[TBL] [Abstract][Full Text] [Related]
27. Immunophenotypic characterization of the bladder mucosa infiltrating lymphocytes after intravesical BCG treatment for superficial bladder carcinoma.
Boccafoschi C; Montefiore F; Pavesi M; Pastormerlo M; Annoscia S; Lozzi C; Betta PG
Eur Urol; 1992; 21(4):304-8. PubMed ID: 1459153
[TBL] [Abstract][Full Text] [Related]
28. Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells.
Luo Y; Knudson MJ
Clin Dev Immunol; 2010; 2010():357591. PubMed ID: 20862387
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant Chemotherapy Reinforces Antitumour T cell Response in Urothelial Urinary Bladder Cancer.
Krantz D; Hartana CA; Winerdal ME; Johansson M; Alamdari F; Jakubczyk T; Huge Y; Aljabery F; Palmqvist K; Zirakzadeh AA; Holmström B; Riklund K; Sherif A; Winqvist O
Eur Urol; 2018 Dec; 74(6):688-692. PubMed ID: 30025882
[TBL] [Abstract][Full Text] [Related]
30. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
Ratliff TL; Palmer JO; McGarr JA; Brown EJ
Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
[TBL] [Abstract][Full Text] [Related]
31. Editor's choice: Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for immunotherapy in bladder cancer.
Watts MR; Taylor PC; Sintchenko V; Whelan CM; Farnsworth RH; Jones P; Jelfs P; Carr D; Goldberg H
Clin Infect Dis; 2011 Jan; 52(1):86-8. PubMed ID: 21148524
[TBL] [Abstract][Full Text] [Related]
32. Role of neutrophils in BCG immunotherapy for bladder cancer.
Simons MP; O'Donnell MA; Griffith TS
Urol Oncol; 2008; 26(4):341-5. PubMed ID: 18593617
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy of Bacillus Calmette‑Guérin by targeting macrophages against bladder cancer in a NOD/scid IL2Rg‑/‑ mouse model.
Tan QL; Zhou CY; Cheng L; Luo M; Liu CP; Xu WX; Zhang X; Zeng X
Mol Med Rep; 2020 Jul; 22(1):362-370. PubMed ID: 32319653
[TBL] [Abstract][Full Text] [Related]
34. Expression of chemokine/cytokine genes and immune cell recruitment following the instillation of Mycobacterium bovis, bacillus Calmette-Guérin or Lactobacillus rhamnosus strain GG in the healthy murine bladder.
Seow SW; Rahmat JN; Bay BH; Lee YK; Mahendran R
Immunology; 2008 Jul; 124(3):419-27. PubMed ID: 18217952
[TBL] [Abstract][Full Text] [Related]
35. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2.
Yamada H; Matsumoto S; Matsumoto T; Yamada T; Yamashita U
J Urol; 2000 Aug; 164(2):526-31. PubMed ID: 10893638
[TBL] [Abstract][Full Text] [Related]
36. Natural Killer Anti-Tumor Activity Can Be Achieved by
Esteso G; Aguiló N; Julián E; Ashiru O; Ho MM; Martín C; Valés-Gómez M
Front Immunol; 2021; 12():622995. PubMed ID: 33708215
[TBL] [Abstract][Full Text] [Related]
37. PMN and anti-tumor immunity--the case of bladder cancer immunotherapy.
Brincks EL; Risk MC; Griffith TS
Semin Cancer Biol; 2013 Jun; 23(3):183-9. PubMed ID: 23410637
[TBL] [Abstract][Full Text] [Related]
38. Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo.
Luo Y; Chen X; O'Donnell MA
Clin Exp Immunol; 2007 Feb; 147(2):370-8. PubMed ID: 17223980
[TBL] [Abstract][Full Text] [Related]
39. Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical Outcome.
Lombardo KA; Murati Amador B; Parimi V; Hoffman-Censits J; Choi W; Hahn NM; Kates M; Bivalacqua TJ; McConkey D; Hoque MO; Matoso A
Appl Immunohistochem Mol Morphol; 2021 Feb; 29(2):127-135. PubMed ID: 32858539
[TBL] [Abstract][Full Text] [Related]
40. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
